Literature DB >> 11172028

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.

M M Addo1, M Altfeld, E S Rosenberg, R L Eldridge, M N Philips, K Habeeb, A Khatri, C Brander, G K Robbins, G P Mazzara, P J Goulder, B D Walker.   

Abstract

The HIV-1 regulatory proteins Rev and Tat are expressed early in the virus life cycle and thus may be important targets for the immune control of HIV-1-infection and for effective vaccines. However, the extent to which these proteins are targeted in natural HIV-1 infection as well as precise epitopes targeted by human cytotoxic T lymphocytes (CTL) remain to be defined. In the present study, 57 HIV-1-infected individuals were screened for responses against Tat and Rev by using overlapping peptides spanning the entire Tat and Rev proteins. CD8+ T cell responses against Tat and Rev were found in up to 19 and 37% of HIV-1-infected individuals, respectively, indicating that these regulatory proteins are important targets for HIV-1-specific CTL. Despite the small size of these proteins, multiple CTL epitopes were identified in each. These data indicate that Tat and Rev are frequently targeted by CTL in natural HIV-1 infection and may be important targets for HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172028      PMCID: PMC29334          DOI: 10.1073/pnas.98.4.1781

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs.

Authors:  J Sidney; H M Grey; R T Kubo; A Sette
Journal:  Immunol Today       Date:  1996-06

2.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.

Authors:  P J Goulder; R E Phillips; R A Colbert; S McAdam; G Ogg; M A Nowak; P Giangrande; G Luzzi; B Morgan; A Edwards; A J McMichael; S Rowland-Jones
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53.

Authors:  K J Smith; S W Reid; K Harlos; A J McMichael; D I Stuart; J I Bell; E Y Jones
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

5.  Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.

Authors:  S Koenig; A J Conley; Y A Brewah; G M Jones; S Leath; L J Boots; V Davey; G Pantaleo; J F Demarest; C Carter
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

6.  Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP).

Authors:  M Bunce; G C Fanning; K I Welsh
Journal:  Tissue Antigens       Date:  1995-02

7.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.

Authors:  D A Price; P J Goulder; P Klenerman; A K Sewell; P J Easterbrook; M Troop; C R Bangham; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

8.  Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection.

Authors:  P J Goulder; M Bunce; P Krausa; K McIntyre; S Crowley; B Morgan; A Edwards; P Giangrande; R E Phillips; A J McMichael
Journal:  AIDS Res Hum Retroviruses       Date:  1996-12-10       Impact factor: 2.205

9.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more
  58 in total

1.  Rapid recruitment of virus-specific CD8 T cells restructures immunodominance during protective secondary responses.

Authors:  Anne E Tebo; Michael J Fuller; Dalia E Gaddis; Kyoko Kojima; Kunal Rehani; Allan J Zajac
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 2.  Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Authors:  Flavia Ferrantelli; Stefano Buttò; Aurelio Cafaro; Britta Wahren; Barbara Ensoli
Journal:  Springer Semin Immunopathol       Date:  2006-09-16

3.  Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire.

Authors:  Dirk Meyer-Olson; Kristen W Brady; Melissa T Bartman; Kristin M O'Sullivan; Brenna C Simons; Joseph A Conrad; Coley B Duncan; Shelly Lorey; Atif Siddique; Rika Draenert; Marylyn Addo; Marcus Altfeld; Eric Rosenberg; Todd M Allen; Bruce D Walker; Spyros A Kalams
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

4.  Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.

Authors:  Bianca R Mothé; Helen Horton; Donald K Carter; Todd M Allen; Max E Liebl; Pam Skinner; Thorsten U Vogel; Sarah Fuenger; Kathy Vielhuber; William Rehrauer; Nancy Wilson; Genoveffa Franchini; John D Altman; Ashley Haase; Louis J Picker; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Impaired plant growth and development caused by human immunodeficiency virus type 1 Tat.

Authors:  Marni E Cueno; Yurina Hibi; Kenichi Imai; Antonio C Laurena; Takashi Okamoto
Journal:  Transgenic Res       Date:  2010-01-20       Impact factor: 2.788

6.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.

Authors:  Karina Yusim; Can Kesmir; Brian Gaschen; Marylyn M Addo; Marcus Altfeld; Søren Brunak; Alexandre Chigaev; Vincent Detours; Bette T Korber
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes.

Authors:  Flavien Bernardin; Denice Kong; Lorraine Peddada; Lee Ann Baxter-Lowe; Eric Delwart
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.